ffrol, I have a theory that Kepivance's blood cancer trials with SOM incidence rates for placebo at 98.1 % and 80 % created this expectation that incidence rate in placebo arm should be high. If you take only head and neck cancer trials placebo arm SOM incidence rates are
Duuesquetide: 73.7 % Validive: 58.1 % Kepivance head and neck 1: 66.0 % Kepivance head and neck 2: 66.0 Brilacidin: 60.0 GC4419: ~ 58.0
As you can see only Dusquetide trial had placebo over 70 %.
Market Data 
Markets 
AI
